Drug or treatment
Donanemab clinical trials
As of November 12, 2026, Find a Trial lists 5 clinical trials of Donanemab that are recruiting, at sites in 7 countries (most in United States (3), Japan (2), Colombia (1)). By phase: Phase 3 (2), Phase 2/3 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 7Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Donanemab follow-up dosing in participants who previously completed TRAILBLAZER-ALZ 3-EXT | Phase 3 | Phoenix, Arizona and 61 other locations | Recruiting | May 22, 2026 |
| Donanemab in Early Cognitive Decline with Lewy Body Features (TRAILBLAZER-ALZ 7) | Phase 2 | Chandler, Arizona and 71 other locations | Recruiting | May 15, 2026 |
| Donanemab in Chinese adults at risk for Alzheimer’s decline | Phase 3 | Beijing and 29 other locations | Recruiting | May 6, 2026 |
| Donanemab and RG6289 in PSEN1 E280A Mutation Carriers with autosomal-dominant Alzheimer’s disease | Phase 2/3 | Medellín, Antioquia | Recruiting | May 30, 2025 |
| Comparing Donanemab with Usual Care for Early Alzheimer's Disease | — | Huntsville, Alabama | Recruiting | Aug 22, 2024 |
All recruiting trials (5)
-
Donanemab follow-up dosing in participants who previously completed TRAILBLAZER-ALZ 3-EXT
This study tests whether giving annual donanemab doses benefits people with Alzheimer's disease who finished the prior trial.
-
Donanemab in Early Cognitive Decline with Lewy Body Features (TRAILBLAZER-ALZ 7)
This trial tests donanemab versus placebo to see if it can slow thinking and daily-function decline in people with early cognitive decline and Lewy body disease features.
-
Donanemab in Chinese adults at risk for Alzheimer’s decline
This study tests donanemab versus placebo in Chinese adults who are cognitively unimpaired but show early signs suggesting they may decline due to Alzheimer’s disease.
-
Donanemab and RG6289 in PSEN1 E280A Mutation Carriers with autosomal-dominant Alzheimer’s disease
Aimed at people with the PSEN1 E280A mutation, this study tests donanemab, RG6289, or both to see if the treatment can slow or alter disease progression.
-
Comparing Donanemab with Usual Care for Early Alzheimer's Disease
This study is testing if adding donanemab to regular care can help people with early Alzheimer's disease feel better over time compared to just sticking with usual care.
Quick answers
How many clinical trials of Donanemab are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 7 countries. The most sites are in United States (3 trials), Japan (2 trials), Colombia (1 trial), China (1 trial), Puerto Rico (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 2, Phase 2/3: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.